Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | PRKCA | P17252 | 3/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713890 | 0.79 | CYP1A2 (0.39) | CYP1A2POLBFASNDAGLAPTPN1 | |
| SCHEMBL10073523 | 0.79 | CYP1A2 (0.39) | CYP1A2POLBFASNDAGLAPTPN1 | |
| SCHEMBL31233823 | 0.74 | — | — | |
| SCHEMBL13282110 | 0.73 | MEN1 (0.38) | CYP1A2POLBFASNDAGLASTAT3 | |
| SCHEMBL9323706 | 0.73 | CYP1A2 (0.40) | CYP1A2POLBFASNDAGLAPTPN1 | |
| SCHEMBL18432999 | 0.72 | POLB (0.54) | POLBFASNDAGLAPTPN1PRKCA | |
| SCHEMBL5195296 | 0.71 | CYP1A2 (0.48) | CYP1A2POLBFASNDAGLAPRKCA | |
| SCHEMBL14715934 | 0.70 | CYP1A2 (0.49) | CYP1A2POLBFASNDAGLAPRKCA | |
| SCHEMBL9618602 | 0.70 | ALDH1A1 (0.44) | CYP1A2POLBFASNPTPN1ACP1 | |
| SCHEMBL6907966 | 0.70 | ALDH1A1 (0.44) | CYP1A2POLBFASNPTPN1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024050-A1 | Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2004-02-05 | — | — | US | disclosed |
| WO-2003088975-A1 | INHIBITION OF FATTY ACID SYNTHASE BY BETA-LACTONES AND OTHER COMPOUNDS FOR INHIBITION OF CELLULAR PROLIFERATION | THE BURNHAM INSTITUTE (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024050-A1 | Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation | FASN, FADS1, FADS2 | CYP1A2 762/4885POLB 1632/4885FASN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.